Fair value measurement - Monte Carlo Simulation (Details) - AbX Biologics, Inc. |
Sep. 30, 2022 |
Dec. 01, 2021 |
|---|---|---|
| Stock price | ||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
| Business combination, contingent consideration | 35.24 | 87.06 |
| Equity volatility | ||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
| Business combination, contingent consideration | 0.937 | 0.813 |
| Risk-free interest rate | ||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
| Business combination, contingent consideration | 0.039 | 0.004 |
| Revenue volatility | ||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
| Business combination, contingent consideration | 0.302 | 0.219 |